NCT00374543 - Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

November 30, 2008

Conditions

Generalized Anxiety DisorderBipolar Disorder

Interventions

DRUG

Ziprasidone

Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.

DRUG

Placebo

Placebo administered daily for 8 weeks

Trial Locations (1)

Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston